ARTICLE

RECENT ADVANCES IN THE TREATMENT OF TUBERCULOSIS INFECTION

  1. HOME
  2. ARTICLE

01 Pages : 1-9

http://dx.doi.org/10.31703/giidr.2019(IV-I).01      10.31703/giidr.2019(IV-I).01      Published : Dec 2019

Recent Advances in the Treatment of Tuberculosis Infection

Abstract

    Tuberculosis (TB) is a centuries old disease which is quite prevalent throughout the world caused by Mycobacterium tuberculosis. This disease kills more people every year than other infectious diseases despite the existence of an effective treatment. This treatment has been available since 1940, which means its existence spans over more than fifty years now. The development of antimicrobial resistance is one of the challenges facing the struggle to stem the tide of this lethal outbreak. The wider range of this disease is linked to few functional factors which include lack of public awareness, patient monitoring and follow-up. The prevalence of great progress and advancement in medical technology and research calls for greater efforts. This review article considers trends prevailing all around the globe in the ailments from a comprehensive perspective.

    Mycobacteria Growth Indicator Tube (MGIT960), Drug Susceptibility Testing (DST), Human Immuno Defficiency Virus (HIV), Multidrug-Resistant TB (MDR-TB), Tuberculosis (TB), Extensively Drug-Resistant T

    (1) Ravish Faiz
    Undergraduate Student, Department of Pharmacy, Quaid-i-Azam University Islamabad, Pakistan.
    (2) Khansha Chaudary
    Undergraduate Student, Department of Pharmacy, Quaid-i-Azam University Islamabad, Pakistan.
    (3) Rabia Saeed
    Undergraduate Student, Department of Pharmacy, Quaid-i-Azam University Islamabad, Pakistan.
    (4) Gul Shehnaz
    Chairperson, Department of Pharmacy, Quaid-i-Azam University Islamabad, Pakistan.
Fulltext PDF

References

  • Allen, A. et al. (2001). ‘Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.45.2.540- 545.2001.
  • Allen, B. W. et al. (1983). 'Amikacin in the treatment of pulmonary tuberculosis', Tubercle. doi: 10.1016/0041-3879(83)90035-1.
  • B., B. & P.C., A. (2004). 'Oxazolidinones: Activity, mode of action, and mechanism of resistance', International Journal of Antimicrobial Agents.
  • Barry, C., Boshoff, H. & Dowd, C. (2005). 'Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis', Current Pharmaceutical Design. doi: 10.2174/1381612043383214.
  • Bemer-Melchior, P., Bryskier, A. & Drugeon, H. B. (2000). ‘Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex', Journal of Antimicrobial Chemotherapy. doi: 10.1093/jac/46.4.571.
  • Brennan, P. J. & Nikaido, H. (1995). 'The envelope of mycobacteria', Annual Review of Biochemistry. doi: 10.1146/annurev.bi.64.070195.000333.
  • Brode, S. K. et al. (2015). ‘Multidrug-resistant tuberculosis: Treatment and outcomes of 93 patients', Canadian Respiratory Journal. doi: 10.1155/2015/359301
  • Brogden, R. N. & Fitton, A. (1994). ‘Rifabutin: A Review of its Antimicrobial Activity, Pharmacokinetic Properties and Therapeutic Efficacy' Drugs. doi: 10.2165/00003495- 199447060-00008.
  • Cambau, E. & Drancourt, M. (2014). ‘Steps towards the discovery of Mycobacterium tuberculosis by Robert Koch, 1882', Clinical Microbiology and Infection. doi: 10.1111/1469-0691.12555.
  • Campbell, E. A. et al. (2001).'Structural mechanism for rifampicin inhibition of bacterial RNA polymerase', Cell. doi: 10.1016/S0092- 8674(01)00286-0.
  • Catanzaro, A. et al. (2015). 'Performance comparison of three rapid tests for the diagnosis of drug- resistant tuberculosis', PLoS ONE. doi: 10.1371/journal.pone.0136861.
  • CDC. (2018) Tuberculosis (TB) Disease: Symptoms and Risk Factors, Centers for Disease Control and Prevention. CDC, C. for disease control and prevention (2012). 'TB Elimination (Multidrug- Resistant Tuberculosis (MDR TB))', Cdc.
  • Coyle, E. A., Kaatz, G. W. & Ryba, M. J. (2001). 'Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.45.6.1654- 1659.2001.
  • Van Crevel, R., Ottenhoff, T. H. M., & Van Der Meer, J. W. M. (2002). 'Innate immunity to tuberculosis', Clinical Microbiology Reviews.
  • Daniel, T. M. (2006) 'The history of tuberculosis', Respiratory Medicine. doi: 10.1016/j.rmed.2006.08.006.
  • Daporta, M. T. et al. (2004). 'In vitro activity of older and newer fluoroquinolones against efflux- mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae', International Journal of Antimicrobial Agents. doi: 10.1016/j.ijantimicag.2004.01.012.
  • Davis, K. K. et al. (2007). 'Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: An observational case series', BMC Pulmonary Medicine. doi: 10.1186/1471-2466- 7-2.
  • Desai, C. R. et al. (1989). 'Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis.', The Journal of the Association of Physicians of India.
  • Dheda, K. et al. (2005). 'Lung remodeling in pulmonary tuberculosis', Journal of Infectious Diseases. doi: 10.1086/444545.
  • Dick, T. (2001). 'Dormant tubercle bacilli: The key to more effective TB chemotherapy [3]', Journal of Antimicrobial Chemotherapy. doi: 10.1093/jac/47.1.117.
  • Ducasse-Cabanot, S. et al. (2004). 'In Vitro Inhibition of the Mycobacterium tuberculosis β-Ketoacyl- Acyl Carrier Protein Reductase MabA by Isoniazid', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.48.1.242- 249.2004.
  • Feklistov, A. et al. (2008). ‘Rifamycins do not function by allosteric modulation of binding of Mg 2 to the RNA polymerase active center', Proceedings of the National Academy of Sciences of the United States of America. doi: 10.1073/pnas.0802822105.
  • Fischer, B., & Ferlinz, R. (1995). 'Therapy and prognosis of tuberculosis', Versicherungsmedizin / herausgegeben von Verband der Lebensversicherungs- Unternehmen e.V. und Verband der Privaten Krankenversicherung e.V.
  • Frith, J. (2014). 'History of tuberculosis. Part 1 - Phthisis, consumption and the white plague', Journal of Military and Veterans' Health.
  • Goering, R. V. et al. (2019). MIMS Medical Microbiology and Immunology, Journal of Visual Languages & Computing.
  • Hu, Y., Coates, A. R. M., & Mitchison, D. A. (2003). 'Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.47.2.653-657.2003.
  • Kawatsu, L., & Uchimura, K. (2016). 'Tuberculosis annual report 2014 -(1) Summary of statistics on tuberculosis notification and foreign-born tuberculosis patients', Kekkaku.
  • Keung, A. et al. (1999) ‘Single and multiple dose pharmacokinetics of rifapentine in man: Part II', International Journal of Tuberculosis and Lung Disease.
  • Leung, A. N. (1999). 'Pulmonary tuberculosis: The essentials', Radiology. doi: 10.1148/radiology.210.2.r99ja34307.
  • Levinson, W. (2014). Review of Medical Microbiology and Immunology, The effects of brief mindfulness intervention on acute pain experience: An examination of individual difference.
  • Merle, C. S. et al. (2014) ‘A Four-Month Gatifloxacin- Containing Regimen for Treating Tuberculosis', New England Journal of Medicine. doi: 10.1056/nejmoa1315817.
  • Milatovic, D. et al. (2000). 'In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.44.4.1102- 1107.2000.
  • Moghazeh, S. L. et al. (1996). ‘Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations', Antimicrobial Agents and Chemotherapy. doi: 10.1128/aac.40.11.2655.
  • Mor, N. et al. (1995). 'Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.39.9.2073.
  • Murugasu-Oei, B. and Dick, T. (2000). ‘Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG', Journal of Antimicrobial Chemotherapy. doi: 10.1093/jac/46.6.917.
  • Pestova, E. et al. (2000) ‘Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones', Journal of Antimicrobial Chemotherapy. doi: 10.1093/jac/45.5.583.
  • Prevention, C., & for, D. C., (2013). 'Core Curriculum on Tuberculosis : What the Clinician Should Know', Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination.
  • Quemard, A., Lacave, C., & Laneelle, G. (1991). ‘Isoniazid inhibition of mycolic acid synthesis by cell extracts of sensitive and resistant strains of Mycobacterium aurum', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.35.6.1035.
  • Ramaswamy, S., & Musser, J. M. (1998). ‘Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update', Tubercle and Lung Disease. doi: 10.1054/tuld.1998.0002.
  • Rouse, D. A. et al. (1995). 'Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.39.11.2472.
  • Rozwarski, D. A. et al. (1998). 'Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis', Science. doi: 10.1126/science.279.5347.98.
  • Ruiz-Serrano, M. J. et al. (2000). 'In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.44.9.2567-2568.2000.
  • Schlünzen, F. et al. (2004). 'Inhibition of peptide bond formation by pleuromutilins: The structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin', Molecular Microbiology. doi: 10.1111/j.1365-2958.2004.04346.x.
  • Scior, T. et al. (2002). 'Antitubercular isoniazid and drug resistance of Mycobacterium tuberculosis - A review', Archiv der Pharmazie. doi: 10.1002/ardp.200290005.
  • Shoen, C. M., DeStefano, M. S., & Cynamon, M. H. (2000). ‘Durable cure for tuberculosis: Rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection', Clinical Infectious Diseases. doi: 10.1086/313876.
  • Slayden, R. A., & Barry, C. E. (2000). ‘The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis', Microbes and Infection. doi: 10.1016/S1286- 4579(00)00359-2.
  • Stover, C. K. et al. (2000). 'A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis', Nature. doi: 10.1038/35016103.
  • du Toit, L. C., Pillay, V., & Danckwerts, M. P. (2006). 'Tuberculosis chemotherapy: Current drug delivery approaches', Respiratory Research. doi: 10.1186/1465-9921-7-118.

Cite this article

APA

CHICAGO

    CHICAGO : Faiz, Ravish, Khansha Chaudary, and Rabia Saeed. 2019. "Recent Advances in the Treatment of Tuberculosis Infection." Global Immunological & Infectious Diseases Review, IV (I): 1-9 doi: 10.31703/giidr.2019(IV-I).01

HARVARD

    HARVARD : FAIZ, R., CHAUDARY, K. & SAEED, R. 2019. Recent Advances in the Treatment of Tuberculosis Infection. Global Immunological & Infectious Diseases Review, IV, 1-9.

MHRA

    MHRA : Faiz, Ravish, Khansha Chaudary, and Rabia Saeed. 2019. "Recent Advances in the Treatment of Tuberculosis Infection." Global Immunological & Infectious Diseases Review, IV: 1-9

MLA

    MLA : Faiz, Ravish, Khansha Chaudary, and Rabia Saeed. "Recent Advances in the Treatment of Tuberculosis Infection." Global Immunological & Infectious Diseases Review, IV.I (2019): 1-9 Print.

OXFORD

    OXFORD : Faiz, Ravish, Chaudary, Khansha, and Saeed, Rabia (2019), "Recent Advances in the Treatment of Tuberculosis Infection", Global Immunological & Infectious Diseases Review, IV (I), 1-9

TURABIAN

    TURABIAN : Faiz, Ravish, Khansha Chaudary, and Rabia Saeed. "Recent Advances in the Treatment of Tuberculosis Infection." Global Immunological & Infectious Diseases Review IV, no. I (2019): 1-9. https://doi.org/10.31703/giidr.2019(IV-I).01